Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibitors

BACKGROUND: There is a lack of real-world data on the use of cabozantinib in Asian patients with metastatic renal cell carcinoma. METHODS: We conducted a retrospective study to investigate the toxicity and efficacy of cabozantinib in this patient population who progressed on tyrosine kinase inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Poon, Darren MC, Chan, Kuen, Leung, Angus Kwong-Chuen, Ng, Brian, Cheung, Foon-Yiu, Siu, Steven Wai-Kwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291967/
https://www.ncbi.nlm.nih.gov/pubmed/37378080
http://dx.doi.org/10.7573/dic.2023-4-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291967/
https://www.ncbi.nlm.nih.gov/pubmed/37378080
http://dx.doi.org/10.7573/dic.2023-4-1

Ejemplares similares